Abbott Laboratories Corporation

Abbvie Inc.

Other

Abbott Gmbh & Co Kg

Richard J Perner

Stanley DiDomenico

Arthur Gomtsyan

Chih-hung Lee

John R Koenig

Erol K Bayburt

Robert G Schmidt

Michael E Kort

Guo Zhu Zheng

Irene I Drizin

Jun Chen

Sean Colm Turner

Anil Vasudevan

Tammie K White

Philip R Kym

Jerome F Daanen

Eric A Voight

John T Randolph

Andrew O Stewart

Michael R Schrimpf

Kevin R Woller

Tao Li

Sachin V Patel

Brian S Brown

Michael P Deninno

Dilinie P Fernando

Margaret Chi-Ping Hsu

Qingwei I Zhang

Zhiren Xia

Heath A McDonald

John F Darbyshire

Biswanath De

George A Doherty

Helmut Mack

Shripad S Bhagwat

John F DeBernardis

Pramila A Bhatia

Michael D Meyer

David M Stout

Fatima Z Basha

Yu-Gui Gu

Daniel P Larson

Chi-nung W Hsiao

Yvonne Connolly Martin

John W Kebabian

Robert W Schoenleber

Qingwei Zhang

Michael P DeNinno

Stanley DiDomenico, Jr

Arthur R Gomtsyan

Chih-Hung Lee

Stanley Didomenico

John Darbyshire

Dilini Fernando

Compounds of formula (I) wherein R, R, R, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPA1 antagonists

Compounds of formula (I) wherein R, R, R, m, and Y are defined in the specification are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds of formula (I) wherein R, R, Rand L are defined in the description are TRPV1 antagonists that exhibit low inhibitory activity against CYP3A4. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds that inhibit TRPV1 and uses thereof

The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z, Z, Z, Z, R, R, and Rare as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.

Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers

The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z', Z&#x2033;, L, G, R, and Rare as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.

[object Object]

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Zand L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar, Ar, L, L, n, R, R, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Compounds as calcium channel blockers

Compounds of formula (I) wherein R, R, R, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R, Rand Rare as defined in the description.

Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Z, and L are defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor

Growing community of inventors

Gurnee, IL, United States of America

Richard J Perner